GlassScriptPhysician profile
Sheila Adkins
NPI 1740649607
$794.81
in general payments reported to CMS, 2019-2025
16 companies · $74.80 in 2025
The $74.80 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $75.43 · 2023: $365 · 2024: $122 · 2025: $74.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $561.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.73 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $105.56 | 2022-2024 | Auvelity |
| Lundbeck LLC | $81.57 | 2023 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $52.37 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $31.13 | 2022-2023 | Abilify Maintena, Rexulti |
| Astrazeneca Pharmaceuticals LP | $29.93 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.70 | 2024 | Ofev |
| Novo Nordisk INC | $18.37 | 2021 | |
| Almatica Pharma LLC | $17.75 | 2023 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $15.25 | 2023 | Trintellix |
| Esperion Therapeutics, INC. | $15.13 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.00 | 2021 | |
| Evoke Pharma, INC. | $13.38 | 2023 | Gimoti |
| Lilly USA, LLC | $13.32 | 2021 | |
| Dexcom, INC. | $12.12 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.